Winton Group’s Soleno Therapeutics SLNO Stock Holding History

Winton Group’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,832	Closed	-$262K	–	1461
2026 Q1	$262K	Sell	7,832 -36,368	-82%	-$1.43M	0.01%	898
2025 Q4	$2.05M	Buy	+44,200	New	+$2.42M	0.07%	306
2021 Q3	–	Sell	-957	Closed	-$16K	–	1470
2021 Q2	$16K	Buy	957 +193	+25%	+$3.26K	﹤0.01%	1408
2021 Q1	$14K	Buy	+764	New	+$24.6K	﹤0.01%	1359

Winton Group's SLNO Position: Q2 2026 in Review

Winton Group sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 7,832 shares — an estimated $262K sold.

Winton Group first reported a position in SLNO in Q1 2021 and held it in 4 quarters. The position peaked at $2.05M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Winton Group reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Winton Group sold 7,832 Soleno Therapeutics shares in Q2 2026, an estimated $262K.
Winton Group first reported a position in Soleno Therapeutics in Q1 2021 and held it in 4 quarters.
Winton Group's Soleno Therapeutics position peaked at $2.05M in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.